Lisanti Capital Growth LLC Acquires Shares of 42,985 Beta Bionics, Inc. $BBNX

Lisanti Capital Growth LLC acquired a new stake in shares of Beta Bionics, Inc. (NASDAQ:BBNX) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 42,985 shares of the company’s stock, valued at approximately $1,310,000. Lisanti Capital Growth LLC owned about 0.10% of Beta Bionics as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Jefferies Financial Group Inc. purchased a new stake in Beta Bionics during the fourth quarter valued at about $1,566,000. Legato Capital Management LLC lifted its holdings in Beta Bionics by 34.6% during the fourth quarter. Legato Capital Management LLC now owns 85,660 shares of the company’s stock valued at $2,610,000 after purchasing an additional 22,035 shares during the last quarter. ProShare Advisors LLC purchased a new stake in Beta Bionics during the fourth quarter valued at about $217,000. Baader Bank Aktiengesellschaft purchased a new stake in shares of Beta Bionics in the fourth quarter worth about $335,000. Finally, First Eagle Investment Management LLC lifted its holdings in shares of Beta Bionics by 8.8% in the fourth quarter. First Eagle Investment Management LLC now owns 253,702 shares of the company’s stock worth $7,730,000 after buying an additional 20,500 shares in the last quarter.

Beta Bionics Price Performance

Shares of NASDAQ BBNX opened at $11.82 on Friday. Beta Bionics, Inc. has a one year low of $8.80 and a one year high of $32.71. The firm’s 50 day simple moving average is $10.58 and its two-hundred day simple moving average is $18.21. The stock has a market capitalization of $526.72 million, a P/E ratio of -7.83 and a beta of 3.29.

Beta Bionics (NASDAQ:BBNX) last issued its quarterly earnings results on Tuesday, April 21st. The company reported ($0.49) EPS for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.04. Beta Bionics had a negative net margin of 60.27% and a negative return on equity of 23.00%. The business had revenue of $27.63 million for the quarter. As a group, equities analysts expect that Beta Bionics, Inc. will post -2.19 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

BBNX has been the topic of a number of recent analyst reports. Wall Street Zen downgraded shares of Beta Bionics from a “hold” rating to a “sell” rating in a report on Sunday, March 29th. TD Cowen initiated coverage on shares of Beta Bionics in a report on Monday, January 26th. They issued a “hold” rating and a $17.00 price target on the stock. Bank of America lowered their price target on shares of Beta Bionics from $23.00 to $11.00 and set a “neutral” rating on the stock in a report on Monday, May 18th. Leerink Partners lowered their target price on shares of Beta Bionics from $25.00 to $24.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 22nd. Finally, UBS Group raised shares of Beta Bionics to a “strong-buy” rating in a research note on Monday, February 9th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Beta Bionics currently has an average rating of “Moderate Buy” and an average price target of $20.00.

Beta Bionics Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.